The latest update is out from Kyverna Therapeutics, Inc. ( (KYTX) ).
Kyverna Therapeutics has appointed Mert Aktar, a seasoned biotech executive with extensive experience in corporate strategy and business development, to its Board of Directors. Aktar, known for his leadership roles in cell therapy and strategic growth in biopharma, is set to enhance Kyverna’s capabilities as it advances its CAR T-cell therapy program for autoimmune diseases. His appointment is expected to bring valuable insights and drive future growth for the company.
Learn more about KYTX stock on TipRanks’ Stock Analysis page.
